**Specifications Table**TableSubject areaMedicineMore specific subject areaOncology, Public health, BiostatisticsType of dataTable and text fileHow data was acquiredSecondary data from University of Maiduguri Teaching Hospital.Data formatRaw and partially analyzed (Descriptive and Inferential)Experimental factorsAnalysis of cancer incidencesExperimental featuresObservations on the age, gender and the topographical location of cancer on the body of affected patientsData source locationUniversity of Maiduguri Teaching hospital, Maiduguri, Borno state, Northeast Nigeria.Data accessibilityAll the data are available this article

**Value of the data**•The data is useful in the study of epidemiology of cancer in the affected areas.•The data is an indication of the public health crisis in insurgency affected region in Nigeria.•The data can be useful in cancer awareness, management and treatment.•The data could be used in oncologic studies.•The data can be used to test the performance of statistical models.

1. Data {#s0005}
=======

The data set represents the age, gender and topological (Top) location of cancer on the body of cancer patients in the University of Maiduguri Teaching hospital located in Maiduguri, the capital of Borno state, Nigeria.

The teaching hospital is the only tertiary health care facility in the state and often serves the other northeast states like Yobe, Taraba, Adamawa, Bauchi and Gombe.

A total of 1671 patients were considered between the period of study and SPSS version 20 was used to perform the analysis. The dataset is available as [Supplementary data](#s0085){ref-type="sec"} while a brief summary of the data is presented in [Table 1](#t0005){ref-type="table"}.Table 1Brief summary of the data.Table 1**Statistics**GenderAgeTopNValid167016711671Missing100Mean1.5350.0637.59Mode2605Variance0.249281.086816.431Skewness−0.115−0.2580.241Std. Error of Skewness0.0600.0600.060Kurtosis−1.989−0.220−1.149Std. Error of Kurtosis0.1200.1200.120Minimum131Maximum295117Sum255383,65862,806

It was observed from [Table 1](#t0005){ref-type="table"} that information about the gender of a patient was not available, hence the missing data of 1.

The frequency distribution of the gender of the patients is presented in [Table 2](#t0010){ref-type="table"}.Table 2Frequency distribution of the patients' gender.Table 2GenderFrequencyPercentCumulative PercentValidMale78747.147.1Female88352.8100.0Total167099.9MissingSystem1.1Total1671100.0[^1]

The frequency distribution of the patients' age is presented in [Table 3](#t0015){ref-type="table"}.Table 3Frequency distribution of the patient\'s age.Table 3Age (years)FrequencyPercentCumulative Percent360.40.4450.30.7510.10.7650.31.0750.31.3820.11.4910.11.51020.11.61240.21.91440.22.11580.52.61660.42.91740.23.21890.53.71960.44.120150.95.02290.55.523120.76.224110.76.925171.07.926110.78.627150.99.528191.110.62970.411.030513.114.13160.414.432221.315.73370.416.234100.616.835744.421.236161.022.137150.923.038271.624.739130.825.440945.631.141130.831.842181.132.943150.933.844110.734.545744.438.946181.140.047130.840.848321.942.749110.743.3501348.051.351120.752.152231.453.453191.154.654231.456.055945.661.656261.663.157181.164.258191.165.45970.465.8601619.675.46190.575.962130.876.76390.577.36480.577.765824.982.66660.483.067100.683.668161.084.66920.184.7701287.792.37150.392.67280.593.17340.293.47430.293.575261.695.17650.395.47750.395.77860.496.17920.196.280362.298.38110.198.48210.198.48310.198.58420.198.685130.899.48620.199.59060.499.99310.199.99510.1100.0Total1671100.0[^2]

The various parts of the body affected by cancer incidences and the number of people affected (frequencies) are indicated in [Table 4](#t0020){ref-type="table"}.Table 4Parts of the body affected by the various types of cancer.Table 4**Topological (Top) location of cancer**FrequencyPercentCumulative PercentValidC77.9 Lymph node, NOS90.50.5C26.9 Gastrointestinal tract, NOS90.51.1C20.9 Rectum, NOS543.24.3C44.9 Skin, NOS472.87.1C61.9 Prostate gland25315.122.3C63.9 Male genital organs, NOS10.122.3C49.6 Soft tissues of trunk50.322.6C50.9 Breast, NOS925.528.1C77.3 Lymph nodes of axilla or arm20.128.2C57.9 Female genital tract, NOS150.929.1C53.9 Cervix uteri764.533.7C22.0 Liver311.935.5C77.0 Lymph nodes of head, face and60.435.9C40.9 Bone of limb, NOS40.236.1C53.8 Overl. lesion of cervix uteri10.136.2C49.2 Soft tissues of lower limb an70.436.6C49.9 Other soft tissues181.137.7C67.9 Urinary bladder, NOS321.939.6C56.9 Ovary603.643.2C40.2 Long bones of lower limb10.143.3C44.2 External ear10.143.3C49.0 Soft tissues of head, face, &90.543.9C44.7 Skin of lower limb and hip60.444.2C39.9 Ill-defined sites within resp150.945.1C49.1 Soft tissues of upper limb, s40.245.4C44.6 Skin of upper limb and shoulder30.245.5C19.9 Rectosigmoid junction40.245.8C64.9 Kidney, NOS201.247.0C40.8 Overl. lesion of bones of lim10.147.0C41.0 Bones of skull and face20.147.2C44.4 Skin of scalp and neck60.447.5C16.3 Gastric antrum60.447.9C18.0 Cecum201.249.1C16.9 Stomach, NOS70.449.5C49.5 Soft tissues of pelvis30.249.7C04.9 Floor of mouth, NOS20.149.8C73.9 Thyroid gland140.850.6C77.1 Intrathoracic lymph nodes10.150.7C52.9 Vagina, NOS80.551.2C10.2 Lateral wall of oropharynx10.151.2C44.5 Skin of trunk20.151.3C69.0 Conjunctiva140.852.2C21.8 Overl. lesion rectum, anal ca90.552.7C49.4 Soft tissues of abdomen40.253.0C18.4 Transverse colon10.153.0C41.9 Bone, NOS10.153.1C76.2 Abdomen, NOS10.153.1C76.5 Lower limb, NOS10.153.2C69.6 Orbit, NOS10.153.3C49.3 Soft tissues of thorax30.253.4C55.9 Uterus, NOS301.855.2C44.8 Overl. lesion of skin10.155.3C51.9 Vulva, NOS10.155.4C10.9 Oropharynx, NOS20.155.5C30.1 Middle ear10.155.5C62.9 Testis, NOS20.155.7C15.0 Cervical esophagus120.756.4C18.7 Sigmoid colon10.156.4C80.9 Unknown primary site20012.068.4C77.2 Intra-abdominal lymph nodes10.168.5C11.9 Nasopharynx, NOS30.268.6C50.0 Nipple16810.178.7C53.0 Endocervix1056.385.0C53.1 Exocervix10.185.0C67.4 Posterior wall of urinary bla80.585.5C16.0 Cardia, NOS332.087.5C21.0 Anus, NOS171.088.5C51.0 Labium majus30.288.7C67.0 Trigone of urinary bladder573.492.1C44.0 Skin of lip, NOS150.993.0C11.0 Superior wall of nasopharynx161.094.0C08.0 Submandibular gland30.294.1C14.0 Pharynx, NOS50.394.4C26.0 Intestinal tract, NOS70.494.9C65.9 Renal pelvis40.295.1C10.0 Vallecula60.495.5C25.0 Head of pancreas50.395.8C60.0 Prepuce40.296.0C21.2 Cloacogenic zone40.296.2C18.6 Descending colon10.196.3C66.9 Ureter10.196.3C50.1 Central portion of breast10.196.4C34.0 Main bronchus10.196.5C21.1 Anal canal30.296.6C18.9 Colon, NOS10.196.7C01.9 Base of tongue, NOS30.296.9C62.0 Undescended testis40.297.1C11.2 Lateral wall of nasopharynx10.197.2C50.6 Axillary tail of breast10.197.2C54.1 Endometrium20.197.4C25.9 Pancreas, NOS10.197.4C30.0 Nasal cavity10.197.5C00.9 Lip, NOS10.197.5C54.2 Myometrium10.197.6C48.8 Overl. lesion of retroperiton10.197.7C76.7 Other ill-defined sites10.197.7C03.0 Upper gum20.197.8C15.9 Oesophagus, NOS10.197.9C69.9 Eye, NOS10.198.0C16.4 Pylorus10.198.0C07.9 Parotid gland20.198.1C67.5 Bladder neck10.198.2C57.4 Uterine adnexa10.198.3C16.2 Body of stomach10.198.3C13.0 Postcricoid region70.498.7C37.9 Thymus10.198.8C17.0 Duodenum10.198.9C06.0 Cheek mucosa10.198.9C04.0 Anterior floor of mouth40.299.2C47.0 Per. nerves & A.N.S. of head,30.299.3C09.0 Tonsillar fossa20.199.5C38.4 Pleura, NOS10.199.5C38.0 Heart40.299.8C67.1 Dome of urinary bladder10.199.8C22.1 Intrahepatic bile duct10.199.9C76.0 Head, face or neck, NOS10.199.9C23.9 Gallbladder10.1100.0Total1671100.0

[Table 4](#t0020){ref-type="table"} shows that the part of the body affected mostly is the prostate gland. This is represented graphically in [Fig. 3](#f0015){ref-type="fig"}.Fig. 1Gender of the patients.Fig. 1Fig. 2Age of the patients.Fig. 2Fig. 3Diagrammatic presentation of the parts of the body affected by cancer.Fig. 3

2. Experimental design, materials and methods {#s0010}
=============================================

The data set was obtained from the patients' records at the data center of the University of Maiduguri teaching hospital. The hospital as stated earlier serves a large population from the six Northeastern states of Nigeria and beyond. The Northeastern region in particular and the entire northern region of the country is in variance with their natural endowments such as vast fertile lands, rivers and lakes for irrigation, mineral resources and abundant sunshine for renewable energy. The weak social structure of the region has resulted to excruciating poverty which often manifest as homelessness and destitution, insurgency, violence and crime [@bib1]. The region has high poverty index, low human development index, lack of portable drinking water, electoral violence, dearth of medical personnel, high mortality, low life expectancy, decayed infrastructure and also an epicenter for joblessness, underage and teenage pregnancy, female genital mutilation, epidemics, illiteracy, malnutrition and now terrorism which comes in form of coordinated attacks on military, police formations and remote villages, guerrilla attacks, kidnappings, regicide, suicide bombings, mass killings, abduction of school girls, extra-judicial killings and summary execution, hypnotizing and forced conscriptions, indoctrination and forceful conversion to Islam and so on. The decadence is assumed to be as a result of corruption, tribalism, military intervention in governance, inequality, misappropriation, financial recklessness, bankrupt of ideas and dearth of developmental agendas, reduction of allocation of capital due to shortfalls of Nigeria revenue as a result of decline in crude oil price. Globally, efforts towards improving the healthcare and reducing the incidence of cancer have yielded desired results except in some developing countries. Hence, cancer related deaths remain stubbornly high in those countries. Cancer awareness, screening, prevention, management, treatment strategies are very low in the region/area studied in this article. Regrettably, capital allocations to the health sector are inadequate and the available funds are often allegedly diverted by corrupt government officials.

In addition, maternal death is one area that is currently affected by the Boko haram insurgency in that region as reported by [@bib2]. Moreover, other areas have been seriously affected; for example; food security and dynamics, under five malnutrition, child mortality, escalation of cholera outbreaks, infections, sexually transmitted diseases, unsafe birth practices and abortion, child prostitution, sex for food at the displaced persons camps, increase in polio cases, See [@bib3], [@bib4], [@bib5], [@bib6], [@bib7], [@bib8] for details. Some related article can also be explored [@bib9], [@bib10], [@bib11], [@bib12], [@bib13], [@bib14], [@bib15], [@bib16], [@bib17], [@bib18], [@bib19], [@bib20], [@bib21], [@bib22], [@bib23], [@bib24], [@bib25], [@bib26], [@bib27], [@bib28], [@bib29], [@bib30], [@bib31].

Next, we analyze the dataset collected using Chi-square test of independence and curve estimation.

2.1. Chi-square test of independence {#s0015}
------------------------------------

Chi-square test of independence was used to investigate the relationship between the location of the cancer (top), gender and age of patients.

### 2.1.1. Test of independency between "Top" and gender of the patients {#s0020}

Hypothesis Testing I:

H~0~: There is no significant association between the topological location of cancer and the gender of the patients.

Versus.

H~1~: There is a significant association between the topological location of cancer and the gender of the patients.

The result of the analysis is presented in [Table 5](#t0025){ref-type="table"}.Table 5Result of the chi-square test between gender and "Top".Table 5**Chi-Square Tests**ValuedfAsymp. Sig. (2-sided)Pearson Chi-Square928.7351160.000Likelihood Ratio1214.0831160.000Linear-by-Linear Association64.65910.000N of Valid Cases1670[^3]

The information about the correlation coefficient and its corresponding *p*-value is presented in [Table 6](#t0030){ref-type="table"}.Table 6Correlation coefficient.Table 6**Symmetric Measures**ValueAsymp. Std. ErrorApprox. *T*Approx. Sig.Interval by IntervalPearson\'s *R*0.1970.0248.1990.000Ordinal by OrdinalSpearman Correlation0.2530.02410.6610.000N of Valid Cases1670

### 2.1.2. Test of independency between "Top" and age of the patients {#s0025}

Hypothesis Testing II:

H~0~: There is no significant association between topological location of cancer is not dependent on the age of the patients.

Versus.

H~1~: There is a significant association between topological location of cancer is dependent on the age of the patients.

The result of the analysis is presented in [Table 7](#t0035){ref-type="table"}.Table 7Result of the chi-square test between age and "Top".Table 7**Chi-Square Tests**ValueDfAsymp. Sig. (2-sided)Pearson Chi-Square10762.73596280.000Likelihood Ratio3148.51696281.000Linear-by-Linear Association50.75810.000N of Valid Cases1671[^4]

Information about the correlation coefficient and its corresponding *p*-value is presented in [Table 8](#t0040){ref-type="table"}.Table 8Correlation coefficient result.Table 8**Symmetric Measures**ValueAsymp. Std. ErrorApprox. *T*Approx. Sig.Interval by IntervalPearson\'s R−.1740.024−7.2330.000Ordinal by OrdinalSpearman Correlation−.1890.025−7.8810.000N of Valid Cases1671

2.2. Curve estimation {#s0030}
---------------------

Linear, logarithmic, inverse, quadratic, cubic, power, growth, exponential and logistic regression models were fitted to the dataset. "Top" is the dependent variable while Age is the independent variable. The summary of the variables used is presented in [Table 9](#t0045){ref-type="table"}.Table 9Summary of the variables.Table 9**Variable Processing Summary**VariablesDependentIndependentTopAgeNumber of Positive Values16711671Number of Zeros00Number of Negative Values00Number of Missing ValuesUser-Missing00System-Missing00

### 2.2.1. Simple linear regression {#s0035}

The summary of the simple linear regression model is presented in [Table 10](#t0050){ref-type="table"}.Table 10Model summary.Table 10*RR* SquareAdjusted *R* SquareStd. Error of the Estimate0.1740.0300.03028.144[^5]

The corresponding analysis of variance (ANOVA) table testing for the fitness of the model is presented in [Table 11](#t0055){ref-type="table"}.Table 11ANOVA table for the linear model.Table 11**ANOVA**Sum of SquaresdfMean Square*F*Sig.Regression41440.679141440.67952.3180.000Residual1321998.7481669792.090Total1363439.4271670[^6]

The linear regression model is significant at 0.05 level of significance and with *R*-square value of 3%.

### 2.2.2. Logarithmic model {#s0040}

The summary of the logarithmic model is presented in [Table 12](#t0060){ref-type="table"}.Table 12Model summary for the logarithmic model.Table 12*RR* SquareAdjusted *R* SquareStd. Error of the Estimate0.1300.0170.01628.340[^7]

Estimating the model parameter gives the result in [Table 13](#t0065){ref-type="table"}.Table 13Parameter estimation for the logarithmic model.Table 13**Coefficients**Unstandardized CoefficientsStandardized Coefficients*T*Sig.*B*Std. ErrorBetaln(Age)−8.1301.520−0.130−5.3490.000(Constant)68.7555.86911.7160.000

The ANOVA table for the logarithmic model is presented in [Table 14](#t0070){ref-type="table"}.Table 14ANOVA table for the logarithmic model.Table 14**ANOVA**Sum of SquaresdfMean Square*F*Sig.Regression22977.216122977.21628.6090.000Residual1340462.2101669803.153Total1363439.4271670[^8]

The logarithmic model is significant at 0.05 level of significance and with R-square value of 1.7%.

### 2.2.3. Inverse model {#s0045}

The summary of the inverse model is presented in [Table 15](#t0075){ref-type="table"}.Table 15Summary of the inverse model.Table 15*RR* SquareAdjusted *R* SquareStd. Error of the Estimate0.0470.0020.00228.550[^9]

The result for the estimation of parameters using the inverse model is presented in [Table 16](#t0080){ref-type="table"}.Table 16Parameter estimation using inverse model.Table 16**Coefficients**Unstandardized CoefficientsStandardized Coefficients*t*Sig.BStd. ErrorBeta1/Age49.54425.6640.0471.9300.054(Constant)36.3270.95638.0180.000

The corresponding ANOVA table is presented in [Table 17](#t0085){ref-type="table"}.Table 17The ANOVA table for the inverse model.Table 17**ANOVA**Sum of SquaresdfMean Square*F*Sig.Regression3037.71913037.7193.7270.054Residual1360401.7071669815.100Total1363439.4271670[^10]

The inverse model is not significant as its *p*-value is greater than the level of significance (0.05).

### 2.2.4. Quadratic model {#s0050}

The summary for the quadratic model is presented in [Table 18](#t0090){ref-type="table"}.Table 18Summary for the quadratic model.Table 18*RR* SquareAdjusted *R* SquareStd. Error of the Estimate0.1950.0380.03728.043[^11]

The result for the estimation of parameter using the quadratic model is presented in [Table 19](#t0095){ref-type="table"}.Table 19Parameter estimation for the quadratic model.Table 19**Coefficients**Unstandardized CoefficientsStandardized Coefficients*t*Sig.*B*Std. ErrorBetaAge0.3480.1830.2041.8970.058Age \*\* 2−0.0070.002−0.388−3.6070.000(Constant)38.9294.3298.9920.000

The corresponding ANOVA table is presented in [Table 20](#t0100){ref-type="table"}.Table 20ANOVA table for the quadratic model.Table 20**ANOVA**Sum of SquaresdfMean Square*F*Sig.Regression51674.289225837.14432.8540.000Residual1311765.1381668786.430Total1363439.4271670[^12]

The quadratic model is significant at 0.05 level of significance and with *R*-square value of 3.8%.

### 2.2.5. Cubic model {#s0055}

The summary for the cubic model is presented in [Table 21](#t0105){ref-type="table"}.Table 21Summary for the cubic model.Table 21*RR* SquareAdjusted *R* SquareStd. Error of the Estimate0.1970.0390.03728.036[^13]

The result for the estimation of parameter for the cubic model is presented in [Table 22](#t0110){ref-type="table"}.Table 22Parameter estimation for the cubic model.Table 22**Coefficients**Unstandardized CoefficientsStandardized Coefficients*t*Sig.*B*Std. ErrorBetaAge0.9510.4770.5581.9930.046Age \*\* 2−0.0210.011−1.230−1.9700.049Age \*\* 30.0000.0000.5041.3690.171(Constant)32.1086.6014.8640.000

The corresponding ANOVA table is presented in [Table 23](#t0115){ref-type="table"}.Table 23ANOVA table for the cubic model.Table 23**ANOVA**Sum of SquaresdfMean Square*F*Sig.Regression53146.668317715.55622.5380.000Residual1310292.7591667786.018Total1363439.4271670[^14]

The cubic model is significant and with *R*-square value of 3.9%.

### 2.2.6. Power model {#s0060}

The summary for the power model is presented in [Table 24](#t0120){ref-type="table"}.Table 24Summary for the power model.Table 24*RR* SquareAdjusted *R* SquareStd. Error of the Estimate0.1590.0250.0251.125[^15]

The result for the estimation of parameter for the power model is presented in [Table 25](#t0125){ref-type="table"}.Table 25Parameter estimation for the power model.Table 25**Coefficients**Unstandardized CoefficientsStandardized Coefficients*t*Sig.*B*Std. ErrorBetaln(Age)−0.3970.060−0.159−6.5830.000(Constant)105.95524.6924.2910.000[^16]

The corresponding ANOVA table is presented in [Table 26](#t0130){ref-type="table"}.Table 26ANOVA table for the power model.Table 26**ANOVA**Sum of SquaresdfMean Square*F*Sig.Regression54.875154.87543.3300.000Residual2113.71016691.266Total2168.5851670[^17]

The power model is significant at 0.05 level of significance and with R-square value of 2.5%.

### 2.2.7. Growth model {#s0065}

The model summary for the growth model is presented in [Table 27](#t0135){ref-type="table"}.Table 27Summary for the growth model.Table 27*RR* SquareAdjusted *R* SquareStd. Error of the Estimate0.2160.0470.0461.113[^18]

The result for the estimation of parameter of the growth model is presented in [Table 28](#t0140){ref-type="table"}.Table 28Parameter estimation for the growth model.Table 28**Coefficients**Unstandardized CoefficientsStandardized Coefficients*t*Sig.*B*Std. ErrorBetaAge−0.0150.002−0.216−9.0380.000(Constant)3.8750.08645.1800.000[^19]

The corresponding ANOVA table is presented in [Table 29](#t0145){ref-type="table"}.Table 29ANOVA table for the growth model.Table 29**ANOVA**Sum of SquaresdfMean Square*F*Sig.Regression101.1811101.18181.6830.000Residual2067.40416691.239Total2168.5851670[^20]

The growth model is significant at 0.05 level of significance and with *R*-square value of 4.7%.

### 2.2.8. Exponential model {#s0070}

The model summary for the exponential model is presented in [Table 30](#t0150){ref-type="table"}.Table 30Summary for the exponential model.Table 30*RR* SquareAdjusted *R* SquareStd. Error of the Estimate0.2160.0470.0461.113[^21]

The result for the estimation of parameter for the exponential model is presented in [Table 31](#t0155){ref-type="table"}.Table 31Parameter estimation for the exponential model.Table 31**Coefficients**Unstandardized CoefficientsStandardized Coefficients*t*Sig.*B*Std. ErrorBetaAge−0.0150.002−0.216−9.0380.000(Constant)48.1734.13211.6600.000[^22]

The corresponding ANOVA table is presented in [Table 32](#t0160){ref-type="table"}.Table 32ANOVA table for the exponential model.Table 32**ANOVA**Sum of SquaresdfMean Square*F*Sig.Regression101.1811101.18181.6830.000Residual2067.40416691.239Total2168.5851670[^23]

The exponential model is significant at 0.05 level of significance and with *R*-square value of 4.7%.

### 2.2.9. Logistic model {#s0075}

The model summary for the logistic model is presented in [Table 33](#t0165){ref-type="table"}.Table 33Summary for the logistic model.Table 33*RR* SquareAdjusted *R* SquareStd. Error of the Estimate0.2160.0470.0461.113[^24]

The estimation of parameters for the logistic model is presented in [Table 34](#t0170){ref-type="table"}.Table 34Parameter estimation for the logistic model.Table 34**Coefficients**Unstandardized CoefficientsStandardized Coefficients*t*Sig.*B*Std. ErrorBetaAge1.0150.0021.241615.5920.000(Constant)0.0210.00211.6600.000[^25]

The corresponding ANOVA table is presented in [Table 35](#t0175){ref-type="table"}.Table 35ANOVA table for the logistic model.Table 35**ANOVA**Sum of SquaresdfMean Square*F*Sig.Regression101.1811101.18181.6830.000Residual2067.40416691.239Total2168.5851670[^26]

The logistic model is also significant at 0.05 level of significance and with *R*-square value of 4.7%.

Lastly, all the fitted models are illustrated in [Fig. 4](#f0020){ref-type="fig"}.Fig. 4The fitted model with respect to the data set.Fig. 4

**Important points**•More females are infected with cancer than men.•The age with the highest record (or incidence) of cancer is 60 years old.•The part of the body that is mostly affected by cancer is the prostate gland (based on the data set collected).•There is a significant association between the topological location of cancer and the gender of the patients.•There is a significant association between the topological location of cancer and the age of the patients.•All the models fitted to the data produced low *R*-square values; nevertheless, the models that best fit the data based on their *R*-square values are growth model, exponential model and logistic model.
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[^1]: **Remark:**[Table 2](#t0010){ref-type="table"} indicates that there are more female patients with cancer diseases than males. This is represented in a pictorial form in [Fig. 1](#f0005){ref-type="fig"}.

[^2]: **Remarks:** From [Table 3](#t0015){ref-type="table"}, the lowest age captured is 3 years old while the oldest patient is 95 years old. The cancer diseases affected both young and old but particularly, the age of the patients with highest number of cancer incidence is 60 years old. This information is represented in [Fig. 2](#f0010){ref-type="fig"}.

[^3]: **Remarks:** The null hypothesis (H~0~) is rejected since the *p*-value (0.000) is less than the level of significance (0.05). Therefore, it can be concluded that there is a significant association between the topological location of cancer and the gender of the patients.

[^4]: **Remarks:** Since the *p*-value is also less than 0.05, we conclude that there is a significant association between the topological location of cancer and the age of the patients.

[^5]: The independent variable is Age.

[^6]: The independent variable is Age.

[^7]: The independent variable is Age.

[^8]: The independent variable is Age.

[^9]: The independent variable is age.

[^10]: The independent variable is age.

[^11]: The independent variable is age.

[^12]: The independent variable is age.

[^13]: The independent variable is age.

[^14]: The independent variable is age.

[^15]: The independent variable is age.

[^16]: The dependent variable is ln(Top).

[^17]: The independent variable is age.

[^18]: The independent variable is age.

[^19]: The dependent variable is ln(Top).

[^20]: The independent variable is age.

[^21]: The independent variable is age.

[^22]: The dependent variable is ln(Top).

[^23]: The independent variable is age.

[^24]: The independent variable is age.

[^25]: The dependent variable is ln(1 / Top).

[^26]: The independent variable is age.
